1
|
Morgan R, Clamp A, Barnes B, Schlecht H, Yarram-Smith L, Wallis Y, Morgan S, Valganon M, Hudson E, McKenna S, Sundar S, Nicum S, Brenton J, Kristeleit R, Banerjee S, McNeish I, Ledermann J, Taylor S, Evans G, Jayson G. 575P Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
2
|
Dillon R, Ahearne MJ, Quek L, Potter N, Jovanovic J, Foot N, Valganon M, Jayne S, Dennis M, Raj K, Tauro S, Dyer MJS, Russell N, Solomon E, Grimwade D. Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis. Leukemia 2021; 35:2407-2411. [PMID: 33547376 PMCID: PMC8324469 DOI: 10.1038/s41375-021-01150-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 01/08/2021] [Accepted: 01/22/2021] [Indexed: 02/06/2023]
Affiliation(s)
- Richard Dillon
- grid.13097.3c0000 0001 2322 6764Department of Medical and Molecular Genetics, King’s College, London, UK ,grid.451052.70000 0004 0581 2008Department of Haematology, Guy’s and St Thomas’ Hospitals NHS Trust, London, UK ,grid.239826.40000 0004 0391 895XCancer Genetics Service, Viapath, Guy’s Hospital, London, UK
| | - Matthew J. Ahearne
- grid.9918.90000 0004 1936 8411The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK
| | - Lynn Quek
- grid.421962.a0000 0004 0641 4431Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK ,grid.13097.3c0000 0001 2322 6764Department of Haematology, King’s College, London, UK
| | - Nicola Potter
- grid.13097.3c0000 0001 2322 6764Department of Medical and Molecular Genetics, King’s College, London, UK
| | - Jelena Jovanovic
- grid.13097.3c0000 0001 2322 6764Department of Medical and Molecular Genetics, King’s College, London, UK
| | - Nicola Foot
- grid.239826.40000 0004 0391 895XCancer Genetics Service, Viapath, Guy’s Hospital, London, UK
| | - Mikel Valganon
- grid.239826.40000 0004 0391 895XCancer Genetics Service, Viapath, Guy’s Hospital, London, UK
| | - Sandrine Jayne
- grid.9918.90000 0004 1936 8411The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK
| | - Mike Dennis
- grid.415720.50000 0004 0399 8363Department of Haematology, The Christie Hospital, Manchester, UK
| | - Kavita Raj
- grid.451052.70000 0004 0581 2008Department of Haematology, Guy’s and St Thomas’ Hospitals NHS Trust, London, UK
| | - Sudhir Tauro
- grid.416266.10000 0000 9009 9462Department of Haematology, Ninewells Hospital and Medical School, Dundee, UK
| | - Martin J. S. Dyer
- grid.9918.90000 0004 1936 8411The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK
| | - Nigel Russell
- grid.451052.70000 0004 0581 2008Department of Haematology, Guy’s and St Thomas’ Hospitals NHS Trust, London, UK
| | - Ellen Solomon
- grid.13097.3c0000 0001 2322 6764Department of Medical and Molecular Genetics, King’s College, London, UK
| | - David Grimwade
- grid.13097.3c0000 0001 2322 6764Department of Medical and Molecular Genetics, King’s College, London, UK
| |
Collapse
|
3
|
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 2020; 135:680-688. [PMID: 31932839 PMCID: PMC7059484 DOI: 10.1182/blood.2019002959] [Citation(s) in RCA: 97] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Accepted: 12/11/2019] [Indexed: 12/15/2022] Open
Abstract
Relapse remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis. Multiple studies have identified the presence of measurable residual disease (MRD) assessed by flow cytometry before alloSCT as a strong predictor of relapse, but it is not clear how these findings apply to patients who test positive in molecular MRD assays, which have far greater sensitivity. We analyzed pretransplant blood and bone marrow samples by reverse-transcription polymerase chain reaction in 107 patients with NPM1-mutant AML enrolled in the UK National Cancer Research Institute AML17 study. After a median follow-up of 4.9 years, patients with negative, low (<200 copies per 105ABL in the peripheral blood and <1000 copies in the bone marrow aspirate), and high levels of MRD had an estimated 2-year overall survival (2y-OS) of 83%, 63%, and 13%, respectively (P < .0001). Focusing on patients with low-level MRD before alloSCT, those with FLT3 internal tandem duplications(ITDs) had significantly poorer outcome (hazard ratio [HR], 6.14; P = .01). Combining these variables was highly prognostic, dividing patients into 2 groups with 2y-OS of 17% and 82% (HR, 13.2; P < .0001). T-depletion was associated with significantly reduced survival both in the entire cohort (2y-OS, 56% vs 96%; HR, 3.24; P = .0005) and in MRD-positive patients (2y-OS, 34% vs 100%; HR, 3.78; P = .003), but there was no significant effect of either conditioning regimen or donor source on outcome. Registered at ISRCTN (http://www.isrctn.com/ISRCTN55675535).
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Female
- Hematopoietic Stem Cell Transplantation/mortality
- Humans
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/mortality
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/mortality
- Neoplasm, Residual/diagnosis
- Neoplasm, Residual/genetics
- Nuclear Proteins/genetics
- Nucleophosmin
- Recurrence
- Young Adult
Collapse
Affiliation(s)
- Richard Dillon
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
- Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom
- Department of Haematology, Guy's Hospital, London, United Kingdom
| | - Robert Hills
- Nuffield Department of Population Health, University of Oxford, United Kingdom
| | - Sylvie Freeman
- Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom
| | - Nicola Potter
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
- Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom
| | - Jelena Jovanovic
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
| | - Adam Ivey
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
| | - Anju Shankar Kanda
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
| | - Manohursingh Runglall
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
| | - Nicola Foot
- Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom
| | - Mikel Valganon
- Cancer Genetics Service, Viapath, Guy's Hospital, London, United Kingdom
| | - Asim Khwaja
- Department of Haematology, University College, London, United Kingdom
| | | | | | | | | | - Mike Dennis
- Christie Hospital, Manchester, United Kingdom
| | - Steven Knapper
- Department of Haematology, Cardiff University, Cardiff, United Kingdom
| | - Harpreet Kaur
- Royal Hallamshire Hospital, Sheffield, United Kingdom
| | | | - Priyanka Mehta
- Bristol Haematology and Oncology Centre, Bristol, United Kingdom
| | - Kavita Raj
- Department of Haematology, Guy's Hospital, London, United Kingdom
| | | | | | | | | | - Kate Hill
- University Hospital, Southampton, United Kingdom
| | | | - Samah Alimam
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
- Department of Haematology, Guy's Hospital, London, United Kingdom
| | - Erin Hurst
- Royal Victoria Infirmary, Newcastle, United Kingdom
| | | | - Anjum Khan
- St James' Hospital, Leeds, United Kingdom
| | - Rahuman Salim
- Clatterbridge Cancer Centre, Liverpool, United Kingdom
| | | | | | - Amanda Gilkes
- Department of Haematology, Cardiff University, Cardiff, United Kingdom
| | - Rosemary Gale
- Department of Haematology, University College, London, United Kingdom
| | - Alan Burnett
- Blackwaterfoot, Isle of Arran, United Kingdom; and
| | - Nigel H Russell
- Department of Haematology, Guy's Hospital, London, United Kingdom
- Nottingham University Hospital, Nottingham, United Kingdom
| | - David Grimwade
- Department of Medical and Molecular Genetics, King's College, London, United Kingdom
- Department of Haematology, Guy's Hospital, London, United Kingdom
| |
Collapse
|
4
|
Kapiris M, Josephs D, Kulkarni A, Valganon M, De Souza B, Campbell J, Churm F, Nickless G, Ross P, De Naurois J, Maisey N, Thillai K, Roca J, George M, Schizas A, Datta V, Westcott E, Sarker D. A retrospective analysis of 66 colorectal cancer cases from Guy’s and St Thomas’ (GSTT) Molecular Tumour Board. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Piskorz AM, Ennis D, Macintyre G, Goranova TE, Eldridge M, Segui-Gracia N, Valganon M, Hoyle A, Orange C, Moore L, Jimenez-Linan M, Millan D, McNeish IA, Brenton JD. Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. Ann Oncol 2016; 27:532-9. [PMID: 26681675 PMCID: PMC4769995 DOI: 10.1093/annonc/mdv613] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 10/29/2015] [Accepted: 12/01/2015] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Next-generation sequencing (NGS) of tumour samples is a critical component of personalised cancer treatment, but it requires high-quality DNA samples. Routine neutral-buffered formalin (NBF) fixation has detrimental effects on nucleic acids, causing low yields, as well as fragmentation and DNA base changes, leading to significant artefacts. PATIENTS AND METHODS We have carried out a detailed comparison of DNA quality from matched samples isolated from high-grade serous ovarian cancers from 16 patients fixed in methanol and NBF. These experiments use tumour fragments and mock biopsies to simulate routine practice, ensuring that results are applicable to standard clinical biopsies. RESULTS Using matched snap-frozen tissue as gold standard comparator, we show that methanol-based fixation has significant benefits over NBF, with greater DNA yield, longer fragment size and more accurate copy-number calling using shallow whole-genome sequencing (WGS). These data also provide a new approach to understand and quantify artefactual effects of fixation using non-negative matrix factorisation to analyse mutational spectra from targeted and WGS data. CONCLUSION We strongly recommend the adoption of methanol fixation for sample collection strategies in new clinical trials. This approach is immediately available, is logistically simple and can offer cheaper and more reliable mutation calling than traditional NBF fixation.
Collapse
Affiliation(s)
- A M Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - D Ennis
- Institute of Cancer Sciences, University of Glasgow, Glasgow
| | - G Macintyre
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - T E Goranova
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - M Eldridge
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge
| | - N Segui-Gracia
- Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, Cambridge
| | - M Valganon
- Cancer Molecular Diagnostics Laboratory, Department of Oncology, University of Cambridge, Cambridge
| | - A Hoyle
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow
| | - C Orange
- Institute of Cancer Sciences, University of Glasgow, Glasgow
| | - L Moore
- Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK
| | - M Jimenez-Linan
- Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK
| | - D Millan
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow
| | - I A McNeish
- Institute of Cancer Sciences, University of Glasgow, Glasgow
| | - J D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge
| |
Collapse
|
6
|
Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, Sriraksa R, El-Kaffash D, El-Etreby N, Natrajan R, Foroni L, Osborne R, El-Bahrawy M. The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget 2016; 7:10568-77. [PMID: 26870997 PMCID: PMC4891141 DOI: 10.18632/oncotarget.7257] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 01/23/2016] [Indexed: 01/22/2023] Open
Abstract
The majority of borderline ovarian tumours (BOTs) behave in a benign fashion, but some may show aggressive behavior. The reason behind this has not been elucidated. The epidermal growth factor receptor (EGFR) is known to contribute to cell survival signals as well as metastatic potential of some tumours. EGFR expression and gene status have not been thoroughly investigated in BOTs as it has in ovarian carcinomas. In this study we explore protein expression as well as gene mutations and amplifications of EGFR in BOTs in comparison to a subset of other epithelial ovarian tumours. We studied 85 tumours, including 61 BOTs, 10 low grade serous carcinomas (LGSCs), 9 high grade serous carcinomas (HGSCs) and 5 benign epithelial tumours. EGFR protein expression was studied using immunohistochemistry. Mutations were investigated by Sanger sequencing exons 18-21 of the tyrosine kinase domain of EGFR. Cases with comparatively higher protein expression were examined for gene amplification by chromogenic in situ hybridization. We also studied the tumours for KRAS and BRAF mutations. Immunohistochemistry results revealed both cytoplasmic and nuclear EGFR expression with variable degrees between tumours. The level of nuclear localization was relatively higher in BOTs and LGSCs as compared to HGSCs or benign tumours. The degree of nuclear expression of BOTs showed no significant difference from that in LGSCs (mean ranks 36.48, 33.05, respectively, p=0.625), but was significantly higher than in HGSCs (mean ranks: 38.88, 12.61 respectively, p< 0.001) and benign tumours (mean ranks: 35.18, 13.00 respectively, p= 0.010). Cytoplasmic expression level was higher in LGSCs. No EGFR gene mutations or amplification were identified, yet different polymorphisms were detected. Five different types of point mutations in the KRAS gene and the V600E BRAF mutation were detected exclusively in BOTs and LGSCs. Our study reports for the first time nuclear localization of EGFR in BOTs. The nuclear localization similarities between BOTs and LGSCs and not HGSCs support the hypothesis suggesting evolution of LGSCs from BOTs. We also confirm that EGFR mutations and amplifications are not molecular events in the pathogenesis of BOTs.
Collapse
Affiliation(s)
- Rania Showeil
- Department of Histopathology, Imperial College London, London, United Kingdom
- Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Claudia Romano
- Imperial Molecular Pathology Laboratory, Imperial College London, London, United Kingdom
| | - Mikel Valganon
- Imperial Molecular Pathology Laboratory, Imperial College London, London, United Kingdom
| | - Maryou Lambros
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Pritesh Trivedi
- Department of Histopathology, Imperial College London, London, United Kingdom
| | - Susan Van Noorden
- Department of Histopathology, Imperial College London, London, United Kingdom
| | - Ruethairat Sriraksa
- Epigenetics Group, International Agency for Research on Cancer, Lyon CEDEX 08, France
| | - Dalal El-Kaffash
- Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Nour El-Etreby
- Obstetrics and Gynaecology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Rachael Natrajan
- Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Letizia Foroni
- Imperial Molecular Pathology Laboratory, Imperial College London, London, United Kingdom
| | - Richard Osborne
- Dorset Cancer Centre, Poole Hospital, Dorset, United Kingdom
| | - Mona El-Bahrawy
- Department of Histopathology, Imperial College London, London, United Kingdom
- Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| |
Collapse
|